Dimerix Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Dimerix için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	15.3%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Dimerix yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

ASX:DXB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	1	-17	-7	-7	N/A
3/31/2024	0	-14	-3	-3	N/A
12/31/2023	9	-11	1	1	N/A
9/30/2023	9	-12	-6	-6	N/A
6/30/2023	0	-14	-13	-13	N/A
3/31/2023	3	-14	-12	-12	N/A
12/31/2022	6	-14	-11	-11	N/A
9/30/2022	6	-12	-12	-12	N/A
6/30/2022	6	-10	-13	-13	N/A
3/31/2022	5	-10	-12	-12	N/A
12/31/2021	4	-9	-11	-11	N/A
9/30/2021	4	-7	-9	-9	N/A
6/30/2021	4	-6	-6	-6	N/A
3/31/2021	3	-6	-5	-5	N/A
12/31/2020	2	-6	-4	-4	N/A
9/30/2020	2	-5	-5	-5	N/A
6/30/2020	2	-4	-5	-5	N/A
3/31/2020	2	-4	-4	-4	N/A
12/31/2019	1	-4	-4	-4	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	1	-3	-3	-3	N/A
12/31/2018	1	-3	-3	-3	N/A
9/30/2018	1	-3	-3	-3	N/A
6/30/2018	1	-3	-3	-3	N/A
3/31/2018	1	-3	N/A	-3	N/A
12/31/2017	1	-3	N/A	-2	N/A
9/30/2017	1	-2	N/A	-2	N/A
6/30/2017	1	-2	N/A	-2	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	1	-3	N/A	-2	N/A
6/30/2016	1	-5	N/A	-1	N/A
3/31/2016	0	-5	N/A	-1	N/A
12/31/2015	0	-5	N/A	-1	N/A
9/30/2015	0	-3	N/A	-1	N/A
6/30/2015	0	-1	N/A	-1	N/A
4/30/2014	0	0	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DXB 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.6% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: DXB 'un kazançlarının Australian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: DXB şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: DXB şirketinin gelirinin Australian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: DXB şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DXB 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Dimerix Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Non Executive Director exercised options to buy AU$70k worth of stock.

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin